Michael E. Kopach

Michael E. Kopach

Auto-generated profile, based on publicly available information

Michael E. Kopach

Eli Lilly and Company

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2019 in The Journal of Organic Chemistry
Verified
Journal Article
Open access
AIAlbert Isidro-Llobet
Albert Isidro-Llobet
MKMartin N. Kenworthy
Martin N. Kenworthy
SMSubha Mukherjee
Subha Mukherjee
MKMichael E. Kopach
Michael E. Kopach
KWKatarzyna Wegner
Katarzyna Wegner
FRFrank Roschangar
Frank Roschangar
In recent years, there has been a growing interest in therapeutic peptides within the pharmaceutical industry with more than 50 peptide drugs on the market, approximately 170 in clinical trials, and >200 in preclinical development. However, the current state of the art in peptide synthesis involves primarily legacy technologies with use of large amounts of highly hazardous reagents and solvents and little focus on green chemistry and engineering. In 2016, the ACS Green Chemistry Institute Pharmaceutical Roundtable identified development of greener processes for peptide API as a critical unmet need, and as a result, a new Roundtable team formed to address this important area. The initial focus of this new team is to highlight best practices in peptide synthesis and encourage much needed innovations. In this Perspective, we aim to summarize the current challenges of peptide synthesis and purification in terms of sustainability, highlight possible solutions, and encourage synergies between academia, the pharmaceutical industry, and contract research organizations/contract manufacturing organizations.

20 March 2024 in The Journal of Organic Chemistry
Verified
Journal Article
Open access
IKIvy Kekessie
Ivy Kekessie
KWKatarzyna Wegner
Katarzyna Wegner
IMIsamir Martinez
Isamir Martinez
MKMichael E. Kopach
Michael E. Kopach
TWTimothy D. White
Timothy D. White
LBLeendert J. van Den Bos
Leendert J. van Den Bos
Small molecule therapeutics represent the majority of the FDA-approved drugs. Yet, many attractive targets are poorly tractable by small molecules, generating a need for new therapeutic modalities. Due to their biocompatibility profile and structural versatility, peptide-based therapeutics are a possible solution. Additionally, in the past two decades, advances in peptide design, delivery, formulation, and devices have occurred, making therapeutic peptides an attractive modality. However, peptide manufacturing is often limited to solid-phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and to a lesser extent hybrid SPPS/LPPS, with SPPS emerging as a predominant platform technology for peptide synthesis. SPPS involves the use of excess solvents and reagents which negatively impact the environment, thus highlighting the need for newer technologies to reduce the environmental footprint. Herein, fourteen American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR) member companies with peptide-based therapeutics in their portfolio have compiled Process Mass Intensity (PMI) metrics to help inform the sustainability efforts in peptide synthesis. This includes PMI assessment on 40 synthetic peptide processes at various development stages in pharma, classified according to the development phase. This is the most comprehensive assessment of synthetic peptide environmental metrics to date. The synthetic peptide manufacturing process was divided into stages (synthesis, purification, isolation) to determine their respective PMI. On average, solid-phase peptide synthesis (SPPS) (PMI ≈ 13,000) does not compare favorably with other modalities such as small molecules (PMI median 168-308) and biopharmaceuticals (PMI ≈ 8300). Thus, the high PMI for peptide synthesis warrants more environmentally friendly processes in peptide manufacturing.

5 January 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
NVNaresh Murty Venneti
Naresh Murty Venneti
GSGanesh Samala
Ganesh Samala
RMRana M. I. Morsy
Rana M. I. Morsy
LMLawrence G. Mendoza
Lawrence G. Mendoza
AIAlbert Isidro-Llobet
Albert Isidro-Llobet
JSJennifer L Stockdill
Jennifer L Stockdill

12 August 2016 in Organic Process Research & Development
Verified
Journal Article
Closed access
MKMichael E. Kopach
Michael E. Kopach
KCKevin P. Cole
Kevin P. Cole
PPPatrick M. Pollock
Patrick M. Pollock
MJMartin D. Johnson
Martin D. Johnson
TBTimothy M. Braden
Timothy M. Braden
MRMorgan Rosemeyer
Morgan Rosemeyer

6 December 2022 in ACS Omega
Verified
Journal Article
Open access
JWJingyao Wang
Jingyao Wang
MBMark R. Berglund
Mark R. Berglund
TBTimothy Braden
Timothy Braden
MEMatthew C. Embry
Matthew C. Embry
MJMartin D. Johnson
Martin D. Johnson
MKMichael E. Kopach
Michael E. Kopach
This study focused on investigating diketopiperazine (DKP) and the formation of associated double-amino-acid deletion impurities during linear solid-phase peptide synthesis (SPPS) of tirzepatide (TZP). We identified that the DKP formation primarily occurred during the Fmoc-deprotection reaction and post-coupling aging of the unstable Fmoc-Pro-Pro-Ser-resin active pharmaceutical ingredient (API) intermediate. Similar phenomena have also been observed for other TZP active pharmaceutical ingredient (API) intermediates that contain a penultimate proline amino acid, such as Fmoc-Ala-Pro-Pro-Pro-Ser-resin, Fmoc-Pro-Pro-Pro-Ser-resin, and Fmoc-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-resin, which are intermediates for both hybrid and linear synthesis approaches. During post-coupling aging, it is found that Fmoc deprotection can proceed in dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), and acetonitrile (ACN) solvents without any piperidine addition. Density functional theory (DFT) calculations showed that a peptide that has a penultimate proline stabilizes the transition state through the C-H···π interaction during Fmoc decomposition, which causes those peptides to be more prone to cascade-deprotection reactions. Pseudo-reaction pathways are then proposed, and a corresponding macrokinetics model is developed to allow accurate prediction of the TZP peptide intermediate self-deprotection and DKP formation rate. Based on those studies, control strategies for minimizing DKP formation were further investigated and an alternative to Fmoc protection was identified (Bsmoc-protected amino acids), which eliminated the formation of the DKP byproducts. In addition, the use of oxyma additives and lower storage temperature was demonstrated to markedly improve the peptide intermediate stability to DKP degradation pathways.